<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00742482</url>
  </required_header>
  <id_info>
    <org_study_id>HL 0101 INT</org_study_id>
    <nct_id>NCT00742482</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of 3 Doses of HL10 Given at Fixed Time Intervals Compared to Standard Therapy</brief_title>
  <official_title>A Phase III Study With Freeze Dried HL10, Three Dosages of 200 mg/kg Ideal Body Weight Versus Standard Therapy in ALI/ARDS Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of three doses of HL 10 given
      at fixed time intervals compared to standard therapy
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    A 300 patient safety analysis by the Data Monitoring Committee showed a trend towards higher
    mortality in the treatment group.
  </why_stopped>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>28 days mortality</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Days alive and off ventilator</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days on ventilation</measure>
    <time_frame>Day 1 to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive and out of ICU</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Pao2/FiO2 ratios and other relevant lung parameters, changes in SOFA score</measure>
    <time_frame>From Day 1 to Day 4, Day 1 to Day 8, Day 4 to Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dead/alive at discharge of ICU</measure>
    <time_frame>Followed until Day 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dear/alive at discharge from hospital</measure>
    <time_frame>Followed until Day 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>180 days mortality</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">418</enrollment>
  <condition>Acute Lung Injury</condition>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HL 10</intervention_name>
    <description>Freeze dried HL 10</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients intubated and on mechanical ventilation

          -  Patients with Acute Lung Injury defined as (a, b, c and d are all applicable): a:
             PaO2/FiO2 &lt; or equal to 300 mmHg (40.0 kPa) (regardless of PEEP level), b: Acute
             onset, c: Pulmonary artery wedge pressure &lt; or equal to 18 mmHg when measured or no
             clinical evidence of left atrial hypertension, d: Bilateral infiltrates seen on
             frontal chest radiograph

          -  Less than 60 hours from onset of the present period of mechanical ventilation to 1st
             instillation

          -  Expected to continue on mechanical ventilation for more than 24 hours

          -  18 years of age or older

          -  Following receipt of verbal and written information about the trial, the patient or
             legally acceptable representative must provide signed and dated informed consent
             before any trial related activity is carried out

        Exclusion Criteria:

          -  Current diagnosis of acute bronchial asthma attack

          -  History of or clinical suspicion of lung fibrosis

          -  Current diagnosis of suspected pulmonary thrombo-embolism

          -  Patients on daily medication for chronic obstructive pulmonary disease at time of
             admission to ICU

          -  Patients who have received mechanical ventilation for more than 48 hours continuously
             within 1 month prior to the present period of mechanical ventilation

          -  Patients with pneumonectomy or lobectomy

          -  Patients with untreated pneumothorax at time of instillation

          -  Patients having tracheostomy at time of instillation

          -  Patients who have had surgical procedures under general anaesthesia performed within 6
             hours prior to inclusion blood gas sample

          -  Patients having mean arterial blood pressure &lt; 50 mmHg in spite of adequate fluid
             administration and/or vasoactive drugs at time of instillation

          -  Patients having PaO2 &lt; 75 mmHg with a FiO2 = 1.0 not responding to adjustment of PEEP
             at time of instillation

          -  Glasgow Coma Score &lt; or equal to 10 before sedation or major findings on CT/MR scan of
             the head such as: brain oedema, acute space occupying lesion, other acute lesions with
             bleeding or mass effect (patients with minor lesion which do not require further
             diagnostics or monitoring can be included)

          -  Patients with life expectancy less than 3 months due to primary disease assessed by
             the attending physician (e.g., end-stage cancer, AIDS or generally poor health)

          -  Known or suspected hypersensitivity to constituents(s) of the investigational product

          -  Patients who have received treatment with any investigational drug within the previous
             4 weeks

          -  Current participation in any other interventional clinical trial until day 29 of the
             trial

          -  Patients previously randomised in this trial

          -  Patients known or suspected of not being able to comply with a study protocol (e.g.,
             due to alcoholism, drug dependency or psychotic state)

          -  Females of childbearing potential who have a positive pregnancy test or who are breast
             feeding

          -  Patients suffering from highly infectious diseases where trial related procedures
             could pose a safety risk for the staff (e.g., SARS)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jozef Kesecioglu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anaesthesist-Intensivist, Department of Intensive Care Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus, Klinik für Anästhesie un Allgemeine Intensivmedizin</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasme University Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital, Critical Care Unit</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital, Intensive Care Unit</name>
      <address>
        <city>Kuopio</city>
        <zip>70211</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié Salpétrière, Département d'Anesthésie Réanimation</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Anästhesiologie der RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1005</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Intensive Care Medicine</name>
      <address>
        <city>Utrecht</city>
        <zip>3584</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ullevål University Hospital, INtensive Care Department</name>
      <address>
        <city>Oslo</city>
        <zip>0407</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorci Hospitalari Parc Taulí</name>
      <address>
        <city>Sabadell (Barcelona)</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Lund, Department of Intensive Care</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Thomas Hospital, Adult Intensive Care</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2008</study_first_submitted>
  <study_first_submitted_qc>August 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2008</study_first_posted>
  <last_update_submitted>February 16, 2009</last_update_submitted>
  <last_update_submitted_qc>February 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2009</last_update_posted>
  <responsible_party>
    <name_title>Edmée Steenken/Project Co-ordinator</name_title>
    <organization>LEO Pharma A/S</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Lung Injury</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

